Ewing Sarcoma’s EWS::FLI1 Trial Just Showed What Precision Oncology Has Been Promising for a Decade
A Nature Medicine phase 1/2 trial of trabectedin plus low-dose irinotecan targeting EWS::FLI1 in Ewing sarcoma signals a new...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
A Nature Medicine phase 1/2 trial of trabectedin plus low-dose irinotecan targeting EWS::FLI1 in Ewing sarcoma signals a new...
Professor Mikael Boesen Professor of Musculoskeletal Radiology & Head of Imaging Research, Copenhagen University Hospital Bispebjerg and Frederiksberg A...
The MASAI trial showed AI-plus-one-radiologist outperforms two radiologists in breast cancer screening. FDA's AI device framework still treats this...
France's March 2026 approval of intravenous racemic ketamine for severe suicidal crisis is the first regulatory action of its...
The EMA's PRAC issued a direct communication to healthcare professionals about severe liver injury linked to cenobamate in April...
France's March 2026 authorization of intravenous racemic ketamine for acute suicidal crisis is the first regulatory approval of its...
IMPROVE-PAH is a two-part adaptive Phase 3 program testing IKT-001, an oral prodrug of imatinib, in up to 180...
Incyclix Bio secured an additional $5 million extension to its Series B from Hatteras Venture Partners to advance INX-315,...
At Week 52 in the Phase 2 COACH trial, once-weekly TransCon CNP plus once-weekly TransCon hGH delivered a mean...
Radiopharm Theranostics’ Phase 1 HEAT trial cleared its second safety gate, with the independent monitoring committee recommending dose escalation...